Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 18, 2011
Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factorsGiuseppe Procopio, Monica Niger, Isabella Testa
Tumori|March 29, 2014
Everolimus in advanced solid tumors: when to start, early or late?Sara Pusceddu, Anna Tessari, Isabella Testa, et al.
Tumori|July 25, 2012
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapyLuigi Celio, Francesco Agustoni, Isabella Testa, et al.
Therapeutic Advances in Urology|December 4, 2012
Experience with sorafenib in the treatment of advanced renal cell carcinomaGiuseppe Procopio, Elena Verzoni, Isabella Testa, et al.
Rare Tumors|January 9, 2015
Response to targeted therapy in urachal adenocarcinomaIsabella Testa, Elena Verzoni, Paolo Grassi, et al.
Future Oncology (London, England)|October 26, 2013
Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicityElena Verzoni, Filippo de Braud, Francesca Fabiani, et al.
Tumori|March 29, 2014
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastasesGiuseppe Procopio, Elena Verzoni, Pamela Biondani, et al.
Anticancer Research|April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patientsPamela Biondani, Elena Verzoni, Valter Torri, et al.
Future Oncology (London, England)|July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factorPaolo Grassi, Elena Verzoni, Luca Porcu, et al.
Pharmacogenomics and Personalized Medicine|April 10, 2014
Targeted treatments in advanced renal cell carcinoma: focus on axitinibElena Verzoni, Paolo Grassi, Isabella Testa, et al.
Pageof 2